Difference between revisions of "Part:BBa K4165083"
Line 17: | Line 17: | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
− | GC% Content | + | GC% Content: 52.1% |
− | 52.1% | + | |
− | Isoelectric point (PI) | + | Isoelectric point (PI): 6.155 |
− | 6.155 | + | |
− | Charge at pH 7 | + | Charge at pH 7: -0.554 |
− | -0.554 | + | |
− | Molecular Weight (Protein) | + | Molecular Weight (Protein): 10.252 kDa |
− | 10.252 kDa | + | |
− | + | ===Dry Lab Characteriztion | |
− | + | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
+ | This inhibitor was modeled by several software and the top model was acquired from Alphafold2 | ||
<html> | <html> |
Revision as of 05:28, 12 October 2022
SPINT3 (Serine Peptidase Inhibitor Kunitz type 3).
This basic part encodes Human serine protease inhibitor known as SPINT3 which is able to inhibit serine peptidases, like HtrA1 (BBa_K4165004).
Usage and Biology
This type of family encodes for a type of inhibitor that is able to inhibit serine proteases and it is predicted to be located extracellularly which interferes with the TGF-β signalling pathway. The inhibitor binds to trypsin-like (serine) proteases and since the catalytic core of HtrA1 (BBa_K4165004) is considered as a tyrpsin-like catalytic domain, so this inhibitor also is considered to inhibit the function of HtrA1 [1] - [4].
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 7
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 7
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 87
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 7
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 7
- 1000COMPATIBLE WITH RFC[1000]
Functional Parameters
GC% Content: 52.1%
Isoelectric point (PI): 6.155
Charge at pH 7: -0.554
Molecular Weight (Protein): 10.252 kDa
===Dry Lab Characteriztion
Modeling
This inhibitor was modeled by several software and the top model was acquired from Alphafold2
Figure 1.: A graphical illustration showing the structure of the inhibitor (AlphaFold).
References
1 - Frochaux, V., Hildebrand, D., Talke, A., Linscheid, M. W., & Schlüter, H. (2014). Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue. PloS one, 9(10), e109483.
2 - Grau, S., Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., ... & Ehrmann, M. (2005). Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proceedings of the National Academy of Sciences, 102(17), 6021-6026.
3 - Eigenbrot, C., Ultsch, M., Lipari, M. T., Moran, P., Lin, S. J., Ganesan, R., ... & Kirchhofer, D. (2012). Structural and functional analysis of HtrA1 and its subdomains. Structure, 20(6), 1040-1050.
4 - Chen, T. J., Tian, Y. F., Chou, C. L., Chan, T. C., He, H. L., Li, W. S., ... & Lai, H. Y. (2021). High spink4 expression predicts poor outcomes among rectal cancer patients receiving CCRT. Current Oncology, 28(4), 2373-2384.